摘要
目的评估JAK(Janus kinase)1抑制剂乌帕替尼和阿布昔替尼对以头颈部表现为主的特应性皮炎的短期疗效和安全性。方法回顾性分析2022年1月-2023年6月在苏州大学附属第一医院皮肤科接受乌帕替尼和阿布昔替尼治疗的以头颈部表现为主的特应性皮炎患者的临床数据。使用湿疹面积和严重程度指数(EASI)、研究者总体评估(IGA)、瘙痒视觉模拟评分(VAS)及体表受累面积(BSA)在治疗的0、2、4、8和12周对患者的临床症状和瘙痒情况进行评分,以评估治疗的疗效和安全性。同时,比较两种治疗方案在达到满意疗效方面的差异。结果共有33例患者纳入研究,其中19例接受乌帕替尼治疗,14例接受阿布昔替尼治疗。研究结果显示,在第12周时,乌帕替尼组和阿布昔替尼组的EASI、VAS、IGA和BSA分值均较治疗前显著下降,差异有统计学意义。此外,乌帕替尼组和阿布昔替尼组在达到满意疗效方面的百分比差异无统计学意义。在不良反应方面,乌帕替尼组和阿布昔替尼组分别有7例和5例患者出现不良反应,其中最常见的不良反应是痤疮和胃肠道不适。结论JAK1抑制剂乌帕替尼和阿布昔替尼治疗以头颈部表现为主的特应性皮炎在短期内显示出良好的疗效和较高的安全性。
Objective To evaluate the short-term efficacy and safety of two Janus kinase(JAK)1 inhibitors,upadacitinib and abrocitinib,in the treatment of atopic dermatitis of the head and neck.Methods This study retrospectively analyzed the clinical data of patients with atopic dermatitis of the head and neck who received upadacitinib and abrocitinib in the Department of Dermatology,the First Affiliated Hospital of Soochow University from January 2022 to June 2023.At 0,2,4,8,and 12 weeks after treatment,clinical symptoms and itching of patients were scored using the eczema area and severity index(EASI),investigator′s glogbal assessment(IGA),visual analogue scale(VAS)itch score,and the body surface area(BSA),to evaluate the efficacy and safety of treatment.Meanwhile,the two treatments were compared in terms of satisfactory efficacy.Results A total of 33 patients were included in the study,including 19 in the upadacitinib group and 14 in the abrocitinib group.At 12 weeks after treatment,EASI,VAS,IGA and BSA scores in both the upadacitinib and abrocitinib groups showed significant declines.Furthermore,there was no significant difference between the upadacitinib and abrocitinib groups in the percentage of patients achieving satisfactory outcomes.In terms of adverse reactions,7 patients in the upadacitinib group and 5 patients in the abrocitinib group had adverse reactions,and the most common adverse reactions were acne and gastrointestinal discomfort respectively.Conclusion The results of this study indicate that JAK1 inhibitors upadacitinib and abrocitinib have good short-term efficacy and high safety in the treatment of atopic dermatitis of the head and neck.
作者
任孙
闵玮
REN Sun;MIN Wei(Department of Dermatovenereology,the First Affiliated Hospital of Soochow University,Suzhou 215000,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2024年第9期989-993,共5页
The Chinese Journal of Dermatovenereology
基金
江苏省中医药科技发展计划项目(MS2021099)。
